Latest Conference Coverage

Defining Progression Independent of Relapsing Activity and Insights into Early Multiple Sclerosis Progression: Emilio Portaccio, MD

The professor of neurology at University of Florence talked about a study presented at ECTRIMS 2024 that validated definitions of progression independent of relapse activity in early relapsing MS. [WATCH TIME: 5 minutes]

Improving Access and Reducing Latency in Genetic Testing for Epilepsy: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

Studying Nerve Cell Therapy NRTX-1001 to Treat Mesial Temporal Lobe Epilepsy: Jonathan Parker, MD, PhD

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]

Advancing Epilepsy Research Through Implementation Science and Biomarkers: Adam Numis, MD; Laura Kirkpatrick, MD

At AES 2024, a duo of pediatric epilepsy specialists discussed how implementation science, validated blood biomarkers, and cross-disciplinary collaboration are advancing epilepsy care and closing research gaps. [WATCH TIME: 3 minutes]

Transforming Neurological Care for Children Through Education, Support, and Collaboration: Jessica Nickrand, PhD; Allyson Eyermann

A duo from Child Neurology Foundation discussed advancing care, providing education for all stakeholders, and offering direct support to families, clinicians, and caregivers navigating neurological conditions for pediatric patients. [WATCH TIME: 5 minutes]

NeuroVoices: Barry Ticho, MD, PhD, on the Disease-Modifying Potential of STK-001 in Treating Dravet Syndrome

The chief medical officer at Stoke Therapeutics sat down at AES 2024 to discuss the promising data behind STK-001, an investigational antisense oligonucleotide in development for Dravet syndrome.

Novel Approach to Antiseizure Drug Development With Use of Long Episodes: Jacqueline A. French, MD

The professor of neurology at NYU Grossman School of Medicine discussed a pioneering study using long seizure episodes to optimize treatment devices and identify effective antiseizure drugs in epilepsy care. [WATCH TIME: 2 minutes]

Using the PERC Database to Gather Insights on Epilepsy Genetics: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of experts talked about 2 studies presented at AES 2024 that used the Pediatric Epilepsy Research Consortium genetics database to study factors influencing latency in genetic testing and drug-resistant epilepsy. [WATCH TIME: 5 minutes]

Addressing Disparities and Improving Care Through Pediatric Epilepsy Research: Adam Numis, MD; Laura Kirkpatrick, MD

At AES 2024, a duo of pediatric epilepsy specialists highlighted a Pediatric Epilepsy Research Consortium review on the need for standardized socio-demographic data and better follow-up for at-risk infants. [WATCH TIME: 5 minutes]

Insights From Child Neurology Foundation on Advancing Holistic Epilepsy Care: Jessica Nickrand, PhD; Allyson Eyermann

A duo from the Child Neurology Foundation discussed multidisciplinary collaboration, innovations in epilepsy care, and the importance of holistic, family-centric approaches to improving patient outcomes at AES 2024. [WATCH TIME: 5 minutes]

Advancing Epilepsy Treatment With Novel Approaches and Predictive Technologies: Jacqueline A. French, MD

The professor of neurology at NYU Grossman School of Medicine discussed how innovative startups are using proof-of-concept studies and devices like responsive neurostimulators to improve patient outcomes. [WATCH TIME: 6 minutes]

Exploring Surgical Advances for Drug-Resistant Epilepsy in Children After Neonatal Stroke

Epileptologists Siddharth Jain, MD, MBBS, and Cemal Karakas, MD, provided commentary on a poster presentation at AES 2024 focusing on factors influencing seizure freedom in children who’ve experienced neonatal and perinatal arterial strokes.

Episode 130: The Promise Behind Cell Therapy Approaches in Epilepsy

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jonathan Parker, MD, PhD. [LISTEN TIME: 23 minutes]

Seizing Hope: UCB’s Advances in Epilepsy and Rare Syndromes

Hugo Xi, head of Medical Neurology at UCB, discussed the company’s groundbreaking research, innovations in epilepsy care, and the company’s commitment to advancing treatments for rare syndromes at the 2024 AES Annual Meeting.

NeuroVoices: Alexander C. Whiting, MD, on Advancing Epilepsy Surgery and Brain Function Research

The director of epilepsy surgery at Allegheny Health Network discussed how clinicians can successfully pinpoint the source of epilepsy in the brain through innovative procedures like stereo electroencephalography.

Promise Behind Stem Cell Approaches to Treat Epilepsy: Jonathan Parker, MD, PhD

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona provided context on the potential of regenerative therapies like stem cells to restore neural function in patients with epilepsy. [WATCH TIME: 3 minutes]

Soticlestat Improves Caregiver and Clinical Measures in ENDYMION 2 Trial of Dravet Syndrome and LGS

Most treatment-emergent adverse events were mild or moderate, with low rates of serious TEAEs leading to discontinuation (1.7% in DS and 2.2% in LGS patients).

AES Poster Highlights Potential Efficacy of Soticlestat in Dravet Syndrome Despite Statistical Hurdle

New data from the phase 3 SKYLINE study suggests soticlestat as a promising adjunctive therapy for seizures among children and young adults living with Dravet syndrome.

Mechanism Behind Novel STK-001 as Disease-Modifying Treatment for Dravet Syndrome: Barry Ticho, MD, PhD

The chief medical officer at Stoke Therapeutics provided commentary on the promising mechanism of action of STK-001, an antisense agent, in the treatment of Dravet syndrome. [WATCH TIME: 3 minutes]

Understanding Clinical Predictors of Response to Nabilone in Alzheimer Agitation

Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.

APOE4 Allele Carriers and Parkinson Disease Named Among Highest Risk Factors for Epilepsy in Patients With Dementia

Factors like education level, hypertension, diabetes, and depression did not significantly predict epilepsy risk in patients with dementia.

Insights on UCB’s Commitment to Advancing Rare Epilepsy Care

Brad Chapman, head of U.S Epilepsy and Rare Syndromes at UCB, provided context on some of the innovative research and studies being presented at the 2024 American Epilepsy Society Annual Meeting.

Fenfluramine Safe and Effective in Lennox-Gastaut Syndrome Regardless of Concomitant Vagus Nerve Stimulation

In both the randomized controlled trial and open-label extension, a higher proportion of patients without VNS achieved at least 50% and 75% seizure reductions compared to those with concomitant VNS treatment.

Therapeutic Optimization of Stiripentol for Dravet Syndrome: James Wheless, MD, FAAP, FAAN, FAES

The Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center highlighted the benefits and challenges of using stiripentol, an FDA-approved treatment for Dravet syndrome. [WATCH TIME: 4 minutes]

AES Poster Provides Safety Insights to Antiseizure Medication Fenfluramine

Fenfluramine showed a consistent safety profile in treating Lennox-Gastaut syndrome, with common adverse events such as decreased appetite, fatigue, and somnolence.

Research Insights on Developmental Epileptic Encephalopathy With Spike Wave Activation in Sleep: Lekha Rao, MD

The epileptologist at UCLA Health provided perspective on a poster presented at AES 2024 that characterized a specific subgroup of patients with developmental epileptic encephalopathy and their response to certain therapies. [WATCH TIME: 3 minutes]

Plasma P-Tau217 Linked to Cognitive Decline and Sleep Disruption in Late-Onset Unexplained Epilepsy

A recent study presented at AES 2024 revealed that plasma p-tau217 linked to memory decline and sleep disruptions in late-onset epilepsy, highlighting its potential as a biomarker.

Claims Analysis Highlights Sleep Apnea Comorbidity as Risk Factor for Increased Mortality in Youths With Epilepsy

Musical Intervention Program May Improve Quality of Life for Pregnant Mothers With Epilepsy

Participants in the intervention group also reported themes of increased connectivity, creativity, and positivity.

Relutrigine Shows Promise in Phase 2 EMBOLD Study of SCN2A-DEE and SCN8A-DEE

Treatment with relutrigine resulted in a 46% placebo-adjusted reduction in motor seizures, along with a well-tolerated safety profile with adverse events that were mild to moderate.